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symptoms 55 and 10 days respectively (p¼ 0.01) and in median initial platelet count
200.000 and 75.000 respectively (p¼ 0.016). Repeating efforts in order to obtain
diagnostic sample of BM should be tried and close observation is important if clinical
symptoms and CBC are suspicious of leukemia.
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Children with Acute Lymphoblastic Leukemia (ALL) treated according to BFM 90
and 95 in our department after remission induction are routinely evaluated as follows:
Bone marrow (BM) four months (mo) from diagnosis (dx) and one mo after therapy
completion, complete blood count (CBC) approximately 101 (77 during maintenance
and 24 the first 4 years off therapy) and physical exam (PE) approximately 42 (18
monthly during maintenance and 24 while off therapy). Of 50 relapses documented
during the study period, 24 -group A- (22 BM, 2 testicular) were diagnosed during
routine evaluation (BM 6, CBC 16, PE 2). Group B included 26 symptomatic relapses
(fever, echymoses, lymphadenopathy, abdominal pain, headache, vomiting, vision
problems), 11 in BM, 6 in central nervous system (CNS), 3 testicular, and combined 6
(BMþCNS 3, BMþ testis 3). Second complete remission (CR) was obtained in 15/
24 (62.5%) of group A and in 20/26 (76.9%) of group B. Overall survival (OS) in
group Awas 29.2% (7/24) for 28-94 mo from relapse (med 53) in CR2 6 and in CR3 1.
OS in group B was 38.5% (10/26) for 5-108 mo from relapse (med 25) all in CR2. Of
388 routine BM 6 were positive (0.015%), of almost 20.000 CBC 16 were positive
(0.0008%) and of almost 8000 PE 2 were suspicious (0.00025%). From this
retrospective study it is shown that routine evaluation in children with ALL may not
depict relapse and therefore may not influence final outcome despite the fact that the
number of relapses which we found is significant (24 versus 26).
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Purpose. Neurotoxicity is a major concern in the treatment of ALL. Rarely
leukoencephalopathy (LEP), a severe treatment-related acute demyelination, is
observed. Neuroradiological imaging and cerebrospinal fluid myelin basic protein
(MBP) levels are potential markers for LEP. We retrospectively analyzed CSF MBP
levels in ALL patients to determine their correlation with development and severity of
chemotherapy-related neurotoxicity. Methods: CSF MBP levels, charts and
neuroradiological reports of ALL patients treated at our institution were reviewed.
Neuroradiological findings were classified into 4 non-exclusive categories: 1/Mild
LEP (localized) 2/Severe LEP (diffuse), 3/Calcifications, 4/Cerebral atrophy.
Neurological symptoms were classified as 1/absent, 2/peripheral neuropathy, 3/
paresis/paralysis, 4/Seizures, 5/Coma. In a subset of patients, long-term follow-up
data and EEG results were analyzed. Statistical analysis was performed using non-
parametric tests. Results: Ninety-eight charts were reviewed. We retrieved 1248
dosages of CSF MBP (84 patients), 381 neurologic examinations (36 patients) and 69
neuroradiological investigations (28 patients). Eighty-four patients (85.7%) had at
least one MBP level done and 53 were abnormal. There was no significant association
between abnormal levels and cranial irradiation(p¼ 0.10), CNS disease at
diagnosis(p¼ 0.13) and sex(p¼ 0.26). Among patients with an abnormal level, 16 had
a neuroimaging study, including 8 with abnormalities described. Six had signs of LEP
(2 severe and 4 mild). Seven had associated clinical symptoms and 4 had an abnormal
EEG. Among the 31 patients who had normal MBP levels, 11 had neuroimaging
studies, 2 showing signs of severe LEP, including one with an abnormal EEG and
seizures. No significant association was found between abnormal MBP and
neuroradiological(p¼ 0.28) or clinical status(p¼ 0.8). Conclusion: CSF MBP levels
did not correlate with imaging or clinical outcome in our patients. Patients with
abnormal MBP levels tend to have abnormal EEGs, but this was statistically not
significant. Based on these data, we stopped routine measurement of CSF MBP in our
ALL patients.
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Objectives. To organize a reference diagnostic service and characterize the clinical,
biologic and treatment outcome features of children with newly diagnosed acute
lymphoblastic leukemia in Lebanon.
Methods. Ninety eight children with ALL were referred for diagnosis from six
institutions in Lebanon between April 2002 and February 2005. Immunophenotyping,
cytogenetics and RT-PCR for t(1;19), t(9;22), t(12;21) and t(4;11) were performed.
Results. The mean age was 6.9 years. There were 1.5M/1F. Seventy nine patients
(81%) had initial white blood counts <50# 109/L. Fifty patients (51%) had initial
WBC <10# 109/L. Eighty five patients (86%) had B-lineage and thirteen patients
(14%) T lineage ALL. Among B-lineage patients 92% expressed CD10 and seventeen
(17.5%) co-expressed myeloid antigens. Eighty patients had cytogenetic evaluation,
this failed in nineteen (23%). Twenty five patients (31%) had normal karyotypes, and
eleven (14%) had >50 chromosomes. Seven patients had (47–50) chromosomes.
Three patients (4%) had t(1;19), five patients (6%) t(9;22). Two patients (2.5%) had
t(4;11). All translocations were confirmed by RT-PCR. Molecular studies for t(12;21)
were positive in thirteen (26%) of 50 patients studied, some of whom had negative or
failed karyotypes. Forty one patients were treated at one institution (CCCL). Twenty
six (63%), thirteen (32%), and two patients with t (9;22) (5%) had low, intermediate
and high risk disease respectively. Two patients died in remission due to sepsis. All
patients with informative translocations, except the two t(9;22), achieved molecular
remissions.
Conclusions. A reference diagnostic service was established. Except for the low
frequency of hyperdiploidy (>50 chromosomes), the presenting features and treatment
outcome of ALL in our patients are similar to those of developed countries. Molecular
diagnosis of t(12;21) was important in risk classification and RT-PCR studies were
also useful for treatment follow up.
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Background. Survival rates for children with Acute Lymphoblastic Leukemia (ALL)
were dramatically improved with the use of methotrexate for CNS chemoprophylaxis.
Objectives. Investigate the incidence and etiology of a sudden increase in MTX
related encephalopathy in Omani patients with pre-B ALL >10 yeas of age.
Design/Methods. This is a retrospective clinical report of a relatively large number
(N¼ 7) of older (>10 years) pediatric ALL patients who developed encephalopathy
while being treated according to MRC ALL 99 protocol. (UK)
Results. In the Sultanate of Oman we began using MRC ALL-99 for ALL patients
from 2000 onwards. Here we describe 7 children with ALL with intermediate risk on
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